CY1120558T1 - Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου - Google Patents

Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου

Info

Publication number
CY1120558T1
CY1120558T1 CY20181100488T CY181100488T CY1120558T1 CY 1120558 T1 CY1120558 T1 CY 1120558T1 CY 20181100488 T CY20181100488 T CY 20181100488T CY 181100488 T CY181100488 T CY 181100488T CY 1120558 T1 CY1120558 T1 CY 1120558T1
Authority
CY
Cyprus
Prior art keywords
4delta30
dengue
chimairikos
anasyndyasmenos
ametafrastis
Prior art date
Application number
CY20181100488T
Other languages
English (en)
Inventor
Stephen S. Whitehead
Brian R. Murphy
Lewis Markoff
Barry Falgout
Joseph Blaney
Kathryn Hanley
Ching-Juh Lai
Original Assignee
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of CY1120558T1 publication Critical patent/CY1120558T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Η εφεύρεση σχετίζεται ένα εμβόλιο για τον ιό του δάγγειου πυρετού που περιέχει χιμαιρικούς ιούς του δάγγειου πυρετού των ορότυπων 1, 2, 3 και 4 που περιλαμβάνουν μια κοινή 30 νουκλεοτιδίων διαγραφή (Δ30) στην 3’-αμετάφραστη περιοχή του γονιδιώματος των ορότυπων 1, 2, 3 και 4 του ιού του δάγγειου πυρετού.
CY20181100488T 2002-05-03 2018-05-14 Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου CY1120558T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37786002P 2002-05-03 2002-05-03
US43650002P 2002-12-23 2002-12-23
EP03724319A EP1554301B1 (en) 2002-05-03 2003-04-25 Dengue vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1 and 2.

Publications (1)

Publication Number Publication Date
CY1120558T1 true CY1120558T1 (el) 2019-07-10

Family

ID=29406814

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100488T CY1120558T1 (el) 2002-05-03 2018-05-14 Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου

Country Status (15)

Country Link
US (7) US7517531B2 (el)
EP (5) EP2338508B1 (el)
JP (1) JP4977811B2 (el)
AT (1) ATE481982T1 (el)
BR (1) BRPI0309631B1 (el)
CA (1) CA2483653C (el)
CY (1) CY1120558T1 (el)
DE (1) DE60334310D1 (el)
DK (2) DK1554301T3 (el)
ES (2) ES2355719T3 (el)
HU (1) HUE037330T2 (el)
PT (2) PT1554301E (el)
SI (2) SI2338508T1 (el)
TR (1) TR201806655T4 (el)
WO (1) WO2003092592A2 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0309631B1 (pt) * 2002-05-03 2021-07-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição
EP1874346B1 (en) 2005-04-24 2014-06-25 Sanofi Pasteur Biologics, LLC Recombinant flavivirus vaccines
JP4549224B2 (ja) * 2005-04-25 2010-09-22 出光ユニテック株式会社 透明ポリプロピレン系樹脂シートの製造方法、透明ポリプロピレン系樹脂シート、及び成形品、並びに透明ポリプロピレン系樹脂シートからなる成形品の白化防止方法、及び温度判別方法
EP1893637B1 (en) * 2005-06-17 2016-01-06 Sanofi Pasteur Dengue serotype 1 attenuated strain
WO2006134443A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 2 attenuated strain
US8017754B2 (en) 2005-07-22 2011-09-13 Research Development Foundation Attenuated virus strains and uses thereof
DK2054428T3 (da) 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
AU2016219680B2 (en) * 2006-08-15 2018-08-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
AU2013263788B2 (en) * 2006-08-15 2016-05-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
JP5620146B2 (ja) 2009-05-22 2014-11-05 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置
JP5623786B2 (ja) 2009-05-22 2014-11-12 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置
KR101117719B1 (ko) * 2009-06-24 2012-03-08 삼성모바일디스플레이주식회사 박막 증착 장치
JP5328726B2 (ja) 2009-08-25 2013-10-30 三星ディスプレイ株式會社 薄膜蒸着装置及びこれを利用した有機発光ディスプレイ装置の製造方法
JP5677785B2 (ja) 2009-08-27 2015-02-25 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置及びこれを利用した有機発光表示装置の製造方法
EP2473624B1 (en) * 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
US8876975B2 (en) 2009-10-19 2014-11-04 Samsung Display Co., Ltd. Thin film deposition apparatus
KR101084184B1 (ko) 2010-01-11 2011-11-17 삼성모바일디스플레이주식회사 박막 증착 장치
KR101174875B1 (ko) 2010-01-14 2012-08-17 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101193186B1 (ko) 2010-02-01 2012-10-19 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101156441B1 (ko) 2010-03-11 2012-06-18 삼성모바일디스플레이주식회사 박막 증착 장치
KR101202348B1 (ko) 2010-04-06 2012-11-16 삼성디스플레이 주식회사 박막 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
US8894458B2 (en) 2010-04-28 2014-11-25 Samsung Display Co., Ltd. Thin film deposition apparatus, method of manufacturing organic light-emitting display device by using the apparatus, and organic light-emitting display device manufactured by using the method
IT1400574B1 (it) 2010-05-06 2013-06-14 Freni Brembo Spa Dispositivo di frenatura a disco per veicoli
US8685649B2 (en) * 2010-06-10 2014-04-01 The United States Of America As Represented By The Secretary Of The Navy RT-LAMP assay for the detection of pan-serotype dengue virus
KR101223723B1 (ko) 2010-07-07 2013-01-18 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
WO2012045063A2 (en) * 2010-10-01 2012-04-05 University Of Rochester Flavivirus domain iii vaccine
KR101738531B1 (ko) 2010-10-22 2017-05-23 삼성디스플레이 주식회사 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101723506B1 (ko) 2010-10-22 2017-04-19 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR20120045865A (ko) 2010-11-01 2012-05-09 삼성모바일디스플레이주식회사 유기층 증착 장치
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
KR20120065789A (ko) 2010-12-13 2012-06-21 삼성모바일디스플레이주식회사 유기층 증착 장치
KR101760897B1 (ko) 2011-01-12 2017-07-25 삼성디스플레이 주식회사 증착원 및 이를 구비하는 유기막 증착 장치
KR101840654B1 (ko) 2011-05-25 2018-03-22 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101852517B1 (ko) 2011-05-25 2018-04-27 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101857249B1 (ko) 2011-05-27 2018-05-14 삼성디스플레이 주식회사 패터닝 슬릿 시트 어셈블리, 유기막 증착 장치, 유기 발광 표시장치제조 방법 및 유기 발광 표시 장치
KR20130004830A (ko) 2011-07-04 2013-01-14 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
KR101826068B1 (ko) 2011-07-04 2018-02-07 삼성디스플레이 주식회사 유기층 증착 장치
KR102015872B1 (ko) 2012-06-22 2019-10-22 삼성디스플레이 주식회사 유기층 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
CA2878599A1 (en) * 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
KR102081284B1 (ko) 2013-04-18 2020-02-26 삼성디스플레이 주식회사 증착장치, 이를 이용한 유기발광 디스플레이 장치 제조 방법 및 유기발광 디스플레이 장치
WO2014204892A1 (en) * 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
NO340722B1 (no) * 2014-06-27 2017-06-06 Norwegian Institute For Agricultural & Environmental Res Transgene planter som uttrykker et rekombinant tetravalent kimært denguevirusantigen for å fremstille effektive vaksiner avledet derfra, samt transgent plastid, plantecelle og frø, rekombinant DNA molekyl, vektor, fremgangsmåter for fremstilling og anvendelse derav
MY192543A (en) 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
US11285202B2 (en) * 2016-01-26 2022-03-29 University Of South Carolina Polymer-protein core-shell particles as effective vaccine delivery vehicles and treatments methods using the same
WO2017156511A1 (en) 2016-03-11 2017-09-14 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Live attenuated zika virus vaccine
MX2018012459A (es) * 2016-04-13 2019-06-06 Takeda Vaccines Inc Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes.
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
CN117752780A (zh) 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂
EP3846848A4 (en) * 2018-09-04 2022-07-06 The Board of Regents of the University of Texas System DNA PLASMID INITIATED LIVE VACCINES FOR PLUS-POLARITY SINGLE STRAND RNA VIRUS
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
WO2023161715A1 (en) * 2022-02-22 2023-08-31 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776638B2 (en) * 1999-03-26 2004-09-16 Walter Reed Army Institute Of Research Adaptation of virus to vertebrate cells
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
CA3060687C (en) * 2001-05-22 2021-05-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
BRPI0309631B1 (pt) * 2002-05-03 2021-07-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição
DK2054428T3 (da) * 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine

Also Published As

Publication number Publication date
BRPI0309631B1 (pt) 2021-07-20
US7517531B2 (en) 2009-04-14
ES2677348T3 (es) 2018-08-01
EP2338508A1 (en) 2011-06-29
HUE037330T2 (hu) 2018-08-28
EP3205352A1 (en) 2017-08-16
PT1554301E (pt) 2010-12-28
US8075903B2 (en) 2011-12-13
WO2003092592A3 (en) 2005-05-19
EP1554301A4 (en) 2006-11-08
BRPI0309631A8 (pt) 2018-09-25
USRE46631E1 (en) 2017-12-12
JP2005532044A (ja) 2005-10-27
US20090258036A1 (en) 2009-10-15
CA2483653A1 (en) 2003-11-13
EP2319532A1 (en) 2011-05-11
ES2355719T3 (es) 2011-03-30
US20070009552A1 (en) 2007-01-11
DE60334310D1 (de) 2010-11-04
EP1554301B1 (en) 2010-09-22
EP2338508B1 (en) 2018-02-14
US20200392469A1 (en) 2020-12-17
SI2338508T1 (en) 2018-07-31
EP1554301A2 (en) 2005-07-20
US9783787B2 (en) 2017-10-10
US11753627B2 (en) 2023-09-12
BRPI0309631A2 (pt) 2016-11-01
AU2003231185A1 (en) 2003-11-17
WO2003092592A2 (en) 2003-11-13
SI1554301T1 (sl) 2011-01-31
USRE46641E1 (en) 2017-12-19
PT2338508T (pt) 2018-05-16
CA2483653C (en) 2014-10-28
US20130011433A1 (en) 2013-01-10
US20180010099A1 (en) 2018-01-11
DK2338508T3 (en) 2018-05-28
EP3763382A1 (en) 2021-01-13
DK1554301T3 (da) 2011-01-24
TR201806655T4 (tr) 2018-06-21
US10837003B2 (en) 2020-11-17
ATE481982T1 (de) 2010-10-15
JP4977811B2 (ja) 2012-07-18

Similar Documents

Publication Publication Date Title
CY1120558T1 (el) Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου
CY1118020T1 (el) Τροποποιημενα φθοριομενα αναλογα νουκλεοζιδιων
ATE297757T1 (de) Chimäre impfstoffe gegen flaviviren
CY1111680T1 (el) Εμβολιο συνδυασμου απενεργοποιημενου ιου πολιομυελiτιδας
UA85536C2 (en) Viral antigens
DK0702085T4 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
NO990025D0 (no) Hamster-EF-1<alfa> transkripsjonsregulatorisk DNA
ATE60800T1 (de) Klonierte dns-sequenzen, hybridisierbar mit genom-rns vom ''lymphadenopathy-associated virus (lav)''.
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
BR0012512B1 (pt) genes de calicivìrus felino e vacinas notadamente vacinas recombinadas.
DE60331758D1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
DE602007008929D1 (de) Parvovirus mit CpG-angereichertem Genom zur Krebstherapie
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DE60233875D1 (de) Attenuierter circovirus
DK76688D0 (da) Vaccine indeholdende f-proteinet fra aids-virus
NO20076452L (no) cDNA construct of Salmonidae alphavirus
CY1117369T1 (el) Εμβολιο για τον δαγγειο πυρετο που περιεχει μια κοινη 30 νουκλεοτιδιων διαγραφη στην 3'-utr των τυπων 1 και 2 ιου του δαγγειου πυρετου
BR9508645A (pt) Vacina da peritonite infecciosa felina
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
BR0318026A (pt) Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos
TH85805B (th) สายพันธุ์ที่ถูกทำให้อ่อนฤทธิ์ของไข้เลือดออกซีโรไทป์ 2
Le Mutational analysis of human RNA polymerase 2 subunit 5 (RPB5): the residues critical for interactions with TF2F subunit RAP30 and hepatitis B virus X protein
TH104137A (th) วัคซีน
RU2003116170A (ru) Рекомбинантная плазмидная днк pbmc-gag(a)mod для экспрессии белка gag вируса иммунодефицита человека в эукариотических клетках
RU2003116168A (ru) Рекомбинантная плазмидная днк рвмс-nef(a)m-1, экспрессирующая белок nef вируса иммунодефицита человека типа 1 в эукариотических клетках